vs
Side-by-side financial comparison of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) and Vistra Corp. (VST). Click either name above to swap in a different company.
Vistra Corp. is the larger business by last-quarter revenue ($4.8B vs $4.7B, roughly 1.0× TEVA PHARMACEUTICAL INDUSTRIES LTD). TEVA PHARMACEUTICAL INDUSTRIES LTD runs the higher net margin — 10.2% vs 4.8%, a 5.4% gap on every dollar of revenue. On growth, Vistra Corp. posted the faster year-over-year revenue change (31.2% vs 11.4%). TEVA PHARMACEUTICAL INDUSTRIES LTD produced more free cash flow last quarter ($1.0B vs $596.0M). Over the past eight quarters, Vistra Corp.'s revenue compounded faster (23.3% CAGR vs 11.1%).
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
Vistra may refer to either of two companies:Vistra, a corporate services company based in Hong Kong Vistra Corp, an energy company based in Texas
TEVA vs VST — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.7B | $4.8B |
| Net Profit | $481.0M | $233.0M |
| Gross Margin | 56.4% | — |
| Operating Margin | 6.4% | 9.9% |
| Net Margin | 10.2% | 4.8% |
| Revenue YoY | 11.4% | 31.2% |
| Net Profit YoY | 321.7% | -47.2% |
| EPS (diluted) | $0.42 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.7B | $4.8B | ||
| Q3 25 | $4.5B | $4.8B | ||
| Q2 25 | $4.2B | $3.8B | ||
| Q1 25 | $3.9B | $4.3B | ||
| Q4 24 | $4.2B | $3.7B | ||
| Q3 24 | $4.3B | $4.3B | ||
| Q2 24 | $4.2B | $3.6B | ||
| Q1 24 | $3.8B | $3.2B |
| Q4 25 | $481.0M | $233.0M | ||
| Q3 25 | $433.0M | $652.0M | ||
| Q2 25 | $282.0M | $327.0M | ||
| Q1 25 | $214.0M | $-268.0M | ||
| Q4 24 | $-217.0M | $441.0M | ||
| Q3 24 | $-437.0M | $1.9B | ||
| Q2 24 | $-846.0M | $365.0M | ||
| Q1 24 | $-139.0M | $-35.0M |
| Q4 25 | 56.4% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 50.3% | — | ||
| Q1 25 | 48.2% | — | ||
| Q4 24 | 50.2% | — | ||
| Q3 24 | 49.6% | — | ||
| Q2 24 | 48.6% | — | ||
| Q1 24 | 46.4% | — |
| Q4 25 | 6.4% | 9.9% | ||
| Q3 25 | 19.7% | 21.7% | ||
| Q2 25 | 10.9% | 13.7% | ||
| Q1 25 | 13.3% | -2.8% | ||
| Q4 24 | -0.7% | 16.4% | ||
| Q3 24 | -1.2% | 59.6% | ||
| Q2 24 | -0.1% | 22.5% | ||
| Q1 24 | -5.7% | 2.7% |
| Q4 25 | 10.2% | 4.8% | ||
| Q3 25 | 9.7% | 13.6% | ||
| Q2 25 | 6.8% | 8.7% | ||
| Q1 25 | 5.5% | -6.3% | ||
| Q4 24 | -5.1% | 12.0% | ||
| Q3 24 | -10.1% | 43.5% | ||
| Q2 24 | -20.3% | 10.1% | ||
| Q1 24 | -3.6% | -1.1% |
| Q4 25 | $0.42 | $0.55 | ||
| Q3 25 | $0.37 | $1.75 | ||
| Q2 25 | $0.24 | $0.81 | ||
| Q1 25 | $0.18 | $-0.93 | ||
| Q4 24 | $-0.19 | $1.09 | ||
| Q3 24 | $-0.39 | $5.25 | ||
| Q2 24 | $-0.75 | $0.90 | ||
| Q1 24 | $-0.12 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.6B | $785.0M |
| Total DebtLower is stronger | — | $15.8B |
| Stockholders' EquityBook value | $7.9B | $5.1B |
| Total Assets | $40.7B | $41.5B |
| Debt / EquityLower = less leverage | — | 3.11× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.6B | $785.0M | ||
| Q3 25 | $2.2B | $602.0M | ||
| Q2 25 | $2.2B | $458.0M | ||
| Q1 25 | $1.7B | $561.0M | ||
| Q4 24 | $3.3B | $1.2B | ||
| Q3 24 | $3.3B | $905.0M | ||
| Q2 24 | $2.3B | $1.6B | ||
| Q1 24 | $3.0B | $1.1B |
| Q4 25 | — | $15.8B | ||
| Q3 25 | — | $15.8B | ||
| Q2 25 | — | $15.5B | ||
| Q1 25 | — | $15.4B | ||
| Q4 24 | — | $15.4B | ||
| Q3 24 | — | $13.9B | ||
| Q2 24 | — | $13.9B | ||
| Q1 24 | — | $14.7B |
| Q4 25 | $7.9B | $5.1B | ||
| Q3 25 | $7.3B | $5.2B | ||
| Q2 25 | $6.8B | $4.8B | ||
| Q1 25 | $6.3B | $4.8B | ||
| Q4 24 | $5.4B | $5.6B | ||
| Q3 24 | $6.1B | $5.4B | ||
| Q2 24 | $6.4B | $5.6B | ||
| Q1 24 | $7.3B | $5.7B |
| Q4 25 | $40.7B | $41.5B | ||
| Q3 25 | $39.9B | $38.0B | ||
| Q2 25 | $40.1B | $38.1B | ||
| Q1 25 | $38.4B | $38.2B | ||
| Q4 24 | $39.3B | $37.8B | ||
| Q3 24 | $41.8B | $37.9B | ||
| Q2 24 | $41.3B | $39.1B | ||
| Q1 24 | $42.8B | $38.2B |
| Q4 25 | — | 3.11× | ||
| Q3 25 | — | 3.02× | ||
| Q2 25 | — | 3.22× | ||
| Q1 25 | — | 3.20× | ||
| Q4 24 | — | 2.77× | ||
| Q3 24 | — | 2.56× | ||
| Q2 24 | — | 2.49× | ||
| Q1 24 | — | 2.60× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.2B | $1.4B |
| Free Cash FlowOCF − Capex | $1.0B | $596.0M |
| FCF MarginFCF / Revenue | 21.6% | 12.4% |
| Capex IntensityCapex / Revenue | 3.0% | 17.4% |
| Cash ConversionOCF / Net Profit | 2.41× | 6.15× |
| TTM Free Cash FlowTrailing 4 quarters | $1.1B | $1.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.2B | $1.4B | ||
| Q3 25 | $369.0M | $1.5B | ||
| Q2 25 | $227.0M | $572.0M | ||
| Q1 25 | $-105.0M | $599.0M | ||
| Q4 24 | $575.0M | $1.4B | ||
| Q3 24 | $693.0M | $1.7B | ||
| Q2 24 | $103.0M | $1.2B | ||
| Q1 24 | $-124.0M | $312.0M |
| Q4 25 | $1.0B | $596.0M | ||
| Q3 25 | $233.0M | $1.0B | ||
| Q2 25 | $131.0M | $-118.0M | ||
| Q1 25 | $-232.0M | $-169.0M | ||
| Q4 24 | $446.0M | $923.0M | ||
| Q3 24 | $545.0M | $1.0B | ||
| Q2 24 | $6.0M | $698.0M | ||
| Q1 24 | $-248.0M | $-153.0M |
| Q4 25 | 21.6% | 12.4% | ||
| Q3 25 | 5.2% | 21.1% | ||
| Q2 25 | 3.1% | -3.1% | ||
| Q1 25 | -6.0% | -4.0% | ||
| Q4 24 | 10.5% | 25.2% | ||
| Q3 24 | 12.6% | 23.4% | ||
| Q2 24 | 0.1% | 19.4% | ||
| Q1 24 | -6.5% | -4.8% |
| Q4 25 | 3.0% | 17.4% | ||
| Q3 25 | 3.0% | 9.6% | ||
| Q2 25 | 2.3% | 18.4% | ||
| Q1 25 | 3.3% | 18.1% | ||
| Q4 24 | 3.1% | 11.7% | ||
| Q3 24 | 3.4% | 15.8% | ||
| Q2 24 | 2.3% | 13.8% | ||
| Q1 24 | 3.2% | 14.7% |
| Q4 25 | 2.41× | 6.15× | ||
| Q3 25 | 0.85× | 2.25× | ||
| Q2 25 | 0.80× | 1.75× | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | — | 3.07× | ||
| Q3 24 | — | 0.90× | ||
| Q2 24 | — | 3.28× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TEVA
| Other | $2.0B | 42% |
| Generics Medicians Including Otc And Biosimilars | $672.0M | 14% |
| Other Products | $608.0M | 13% |
| License | $529.0M | 11% |
| Distribution Service | $366.0M | 8% |
| Other Activities | $227.0M | 5% |
| Ajovy | $106.0M | 2% |
| COPAXONE | $77.0M | 2% |
| Respiratory Product | $65.0M | 1% |
| Uzedy | $55.0M | 1% |
| Bendeka And Treanda | $36.0M | 1% |
VST
| Retail Energy Charge In ERCOT | $2.1B | 43% |
| Retail Energy Charge In Northeast Midwest | $1.2B | 24% |
| East Segment | $1.1B | 24% |
| Hedging Revenue Realized | $170.0M | 4% |
| Revenue From Other Wholesale Contracts | $116.0M | 2% |
| Transferable Production Tax Credit Revenues | $78.0M | 2% |
| West Segment | $77.0M | 2% |
| Intersegment Sales | $25.0M | 1% |
